Cargando…

Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma

INTRODUCTION: Over the years, the molecular classification of endometrial carcinoma has evolved significantly. Both POLEmut and MMRdef cases share tumor biological similarities like high tumor mutational burden and induce strong lymphatic reactions. While therefore use case scenarios for pretesting...

Descripción completa

Detalles Bibliográficos
Autores principales: Jungen, Samuel H., Noti, Luca, Christe, Lucine, Galvan, Jose A., Zlobec, Inti, Müller, Michael D., Imboden, Sara, Siegenthaler, Franziska, Carlson, Joseph W., Pellinen, Teijo, Heredia-Soto, Victoria, Ruz-Caracuel, Ignacio, Hardisson, David, Redondo, Andres, Mendiola, Marta, Rau, Tilman T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076655/
https://www.ncbi.nlm.nih.gov/pubmed/37035329
http://dx.doi.org/10.3389/fmed.2023.1110529
_version_ 1785020179502071808
author Jungen, Samuel H.
Noti, Luca
Christe, Lucine
Galvan, Jose A.
Zlobec, Inti
Müller, Michael D.
Imboden, Sara
Siegenthaler, Franziska
Carlson, Joseph W.
Pellinen, Teijo
Heredia-Soto, Victoria
Ruz-Caracuel, Ignacio
Hardisson, David
Redondo, Andres
Mendiola, Marta
Rau, Tilman T.
author_facet Jungen, Samuel H.
Noti, Luca
Christe, Lucine
Galvan, Jose A.
Zlobec, Inti
Müller, Michael D.
Imboden, Sara
Siegenthaler, Franziska
Carlson, Joseph W.
Pellinen, Teijo
Heredia-Soto, Victoria
Ruz-Caracuel, Ignacio
Hardisson, David
Redondo, Andres
Mendiola, Marta
Rau, Tilman T.
author_sort Jungen, Samuel H.
collection PubMed
description INTRODUCTION: Over the years, the molecular classification of endometrial carcinoma has evolved significantly. Both POLEmut and MMRdef cases share tumor biological similarities like high tumor mutational burden and induce strong lymphatic reactions. While therefore use case scenarios for pretesting with tumor-infiltrating lymphocytes to replace molecular analysis did not show promising results, such testing may be warranted in cases where an inverse prediction, such as that of POLEwt, is being considered. For that reason we used a spatial digital pathology method to quantitatively examine CD3(+) and CD8(+) immune infiltrates in comparison to conventional histopathological parameters, prognostics and as potential pretest before molecular analysis. METHODS: We applied a four-color multiplex immunofluorescence assay for pan-cytokeratin, CD3, CD8, and DAPI on 252 endometrial carcinomas as testing and compared it to further 213 cases as validation cohort from a similar multiplexing assay. We quantitatively assessed immune infiltrates in microscopic distances within the carcinoma, in a close distance of 50 microns, and in more distant areas. RESULTS: Regarding prognostics, high CD3(+) and CD8(+) densities in intra-tumoral and close subregions pointed toward a favorable outcome. However, TCGA subtyping outperforms prognostication of CD3 and CD8 based parameters. Different CD3(+) and CD8(+) densities were significantly associated with the TCGA subgroups, but not consistently for histopathological parameter. In the testing cohort, intra-tumoral densities of less than 50 intra-tumoral CD8(+) cells/mm(2) were the most suitable parameter to assume a POLEwt, irrespective of an MMRdef, NSMP or p53abn background. An application to the validation cohort corroborates these findings with an overall sensitivity of 95.5%. DISCUSSION: Molecular confirmation of POLEmut cases remains the gold standard. Even if CD3(+) and CD8(+) cell densities appeared less prognostic than TCGA, low intra-tumoral CD8(+) values predict a POLE wild-type at substantial percentage rates, but not vice versa. This inverse correlation might be useful to increase pretest probabilities in consecutive POLE testing. Molecular subtyping is currently not conducted in one-third of cases deemed low-risk based on conventional clinical and histopathological parameters. However, this percentage could potentially be increased to two-thirds by excluding sequencing of predicted POLE wild-type cases, which could be determined through precise quantification of intra-tumoral CD8(+) cells.
format Online
Article
Text
id pubmed-10076655
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100766552023-04-07 Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma Jungen, Samuel H. Noti, Luca Christe, Lucine Galvan, Jose A. Zlobec, Inti Müller, Michael D. Imboden, Sara Siegenthaler, Franziska Carlson, Joseph W. Pellinen, Teijo Heredia-Soto, Victoria Ruz-Caracuel, Ignacio Hardisson, David Redondo, Andres Mendiola, Marta Rau, Tilman T. Front Med (Lausanne) Medicine INTRODUCTION: Over the years, the molecular classification of endometrial carcinoma has evolved significantly. Both POLEmut and MMRdef cases share tumor biological similarities like high tumor mutational burden and induce strong lymphatic reactions. While therefore use case scenarios for pretesting with tumor-infiltrating lymphocytes to replace molecular analysis did not show promising results, such testing may be warranted in cases where an inverse prediction, such as that of POLEwt, is being considered. For that reason we used a spatial digital pathology method to quantitatively examine CD3(+) and CD8(+) immune infiltrates in comparison to conventional histopathological parameters, prognostics and as potential pretest before molecular analysis. METHODS: We applied a four-color multiplex immunofluorescence assay for pan-cytokeratin, CD3, CD8, and DAPI on 252 endometrial carcinomas as testing and compared it to further 213 cases as validation cohort from a similar multiplexing assay. We quantitatively assessed immune infiltrates in microscopic distances within the carcinoma, in a close distance of 50 microns, and in more distant areas. RESULTS: Regarding prognostics, high CD3(+) and CD8(+) densities in intra-tumoral and close subregions pointed toward a favorable outcome. However, TCGA subtyping outperforms prognostication of CD3 and CD8 based parameters. Different CD3(+) and CD8(+) densities were significantly associated with the TCGA subgroups, but not consistently for histopathological parameter. In the testing cohort, intra-tumoral densities of less than 50 intra-tumoral CD8(+) cells/mm(2) were the most suitable parameter to assume a POLEwt, irrespective of an MMRdef, NSMP or p53abn background. An application to the validation cohort corroborates these findings with an overall sensitivity of 95.5%. DISCUSSION: Molecular confirmation of POLEmut cases remains the gold standard. Even if CD3(+) and CD8(+) cell densities appeared less prognostic than TCGA, low intra-tumoral CD8(+) values predict a POLE wild-type at substantial percentage rates, but not vice versa. This inverse correlation might be useful to increase pretest probabilities in consecutive POLE testing. Molecular subtyping is currently not conducted in one-third of cases deemed low-risk based on conventional clinical and histopathological parameters. However, this percentage could potentially be increased to two-thirds by excluding sequencing of predicted POLE wild-type cases, which could be determined through precise quantification of intra-tumoral CD8(+) cells. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076655/ /pubmed/37035329 http://dx.doi.org/10.3389/fmed.2023.1110529 Text en Copyright © 2023 Jungen, Noti, Christe, Galvan, Zlobec, Müller, Imboden, Siegenthaler, Carlson, Pellinen, Heredia-Soto, Ruz-Caracuel, Hardisson, Redondo, Mendiola and Rau. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Jungen, Samuel H.
Noti, Luca
Christe, Lucine
Galvan, Jose A.
Zlobec, Inti
Müller, Michael D.
Imboden, Sara
Siegenthaler, Franziska
Carlson, Joseph W.
Pellinen, Teijo
Heredia-Soto, Victoria
Ruz-Caracuel, Ignacio
Hardisson, David
Redondo, Andres
Mendiola, Marta
Rau, Tilman T.
Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma
title Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma
title_full Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma
title_fullStr Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma
title_full_unstemmed Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma
title_short Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma
title_sort spatial distribution of cd3- and cd8-positive lymphocytes as pretest for pole wild-type in molecular subgroups of endometrial carcinoma
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076655/
https://www.ncbi.nlm.nih.gov/pubmed/37035329
http://dx.doi.org/10.3389/fmed.2023.1110529
work_keys_str_mv AT jungensamuelh spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT notiluca spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT christelucine spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT galvanjosea spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT zlobecinti spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT mullermichaeld spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT imbodensara spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT siegenthalerfranziska spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT carlsonjosephw spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT pellinenteijo spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT herediasotovictoria spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT ruzcaracuelignacio spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT hardissondavid spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT redondoandres spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT mendiolamarta spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma
AT rautilmant spatialdistributionofcd3andcd8positivelymphocytesaspretestforpolewildtypeinmolecularsubgroupsofendometrialcarcinoma